Table 3.
Current ongoing trials.
| Study Number | Target | Treatment | Evidence |
|---|---|---|---|
| NCT03072641 | Colon Cancer | Probiotics | Randomized |
| NCT03048500 | NSCLC | Metformin Hydrocloride + Nivolumab | Phase 2 |
| NCT03311308 | Melanoma | Metformin + Pembrolizumab vs. Pembrolizumab | Randomized double blind |
| NCT03048500 | NSCLC | Metformin + Nivolumab | Randomized, Phase 2 |
| NCT03314935 | Advanced or Metastatic solid tumors | INCB001158 (Arginase inhibitors) + chemotherapy | Phase 1/2 |
| NCT02903914 | Advanced or Metastatic solid tumors | INCB001158 (Arginase inhibitors) +/− immune checkpoint therapy | Phase 1 |
| NCT03047928 | Melanoma | PDL1/IDO Vaccine + Nivolumab | Phase 1/2 |
| NCT03291054 | GIST | Epacadostat + Pembrolizumab | Phase 2 |
| NCT01604889 | Melanoma | Epacadostat + Ipilimumab | Phase 1/2 randomized, blinded |
| NCT02861300 | Colon Cancer | CB-839 (oral glutaminase inhibitor) + Capecitabine | Phase 1/2 |
| NCT03428217 | Renal cell carcinoma | CB-839 (oral glutaminase inhibitor) + Cabozantinib vs. Cabozantinib | Phase 2, double blind randomized |
NSCLC: non-small cell lung cancer. PDL1: Programmed death-ligand 1. IDO: Indoleamine 2, 3-Dioxygenase. GIST: Gastrointestinal stromal tumor.